CommercialPrior AuthMedium impact
08.01.01o, Ipilimumab (Yervoy®)
Independence Blue Cross·Oncology, Pharmacy·Pharmacy
Effective date
Dec 29, 2025
We identified it
Jun 19, 2026
Summary
Policy 08.01.01o for Ipilimumab (Yervoy®) has been updated effective 12/29/2025 with changes to medical necessity criteria, medical coding requirements, and general guidelines. The billing team must review updated authorization requirements and coding rules to ensure compliant claim submission for this immunotherapy drug.
Action Required
By 12/29/2025: Billing team must obtain and review the complete policy text at https://medpolicy.ibx.com/ibc/Commercial/Pages/Site-Activity-View.aspx?FilterField1=MPSiteActivityLogMonth&FilterValue1=12&FilterField2=MPSiteActivityLogYear&FilterValue2=2025#commercial-08-01-01o. Update prior authorization workflows, billing codes, and medical necessity documentation requirements in the billing system and provider encounter forms to align with the new criteria. Communicate updated requirements to oncology providers and pharmacy staff. Claims submitted without adherence to updated medical necessity criteria will be denied.